Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Price Performance

GILD stock traded up $2.93 during midday trading on Tuesday, reaching $127.23. 9,381,571 shares of the company’s stock traded hands, compared to its average volume of 7,008,783. The company has a 50-day simple moving average of $132.86 and a two-hundred day simple moving average of $134.32. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29. The company has a market cap of $157.96 billion, a price-to-earnings ratio of 17.33 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same period last year, the firm posted $1.81 EPS. The business’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares in the last quarter. Quattro Advisors LLC bought a new position in Gilead Sciences during the fourth quarter worth about $26,000. Wealth Preservation Advisors LLC lifted its holdings in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Wilkerson Advisory Group LLC lifted its holdings in Gilead Sciences by 54.2% during the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 78 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on GILD shares. Morgan Stanley reduced their price target on Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Barclays started coverage on Gilead Sciences in a research report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. Citigroup raised their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Finally, Argus raised their price target on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.41.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA accepted Gilead’s filing for Yeztugo, a potential once-weekly oral HIV prevention pill. If approved, it could expand Gilead’s PrEP offering and strengthen its long-term HIV revenue stream. Article Title
• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and set a $155 price target, implying meaningful upside from current levels and reinforcing a bullish analyst view on Gilead’s pipeline and earnings outlook.
• Positive Sentiment: Recent commentary also highlighted Gilead’s growing momentum in liver disease after approvals and trial progress in that area, which could diversify growth beyond HIV and improve investor confidence. Article Title
• Neutral Sentiment: The FDA assigned a PDUFA date of February 2, 2027 for Yeztugo, meaning the catalyst is important but still months away, so the near-term impact is limited.
• Negative Sentiment: Gilead shares have recently traded below their 50-day and 200-day moving averages, suggesting the stock still faces technical headwinds despite the latest positive developments.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.